Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC vs glycopyrronium in COPD (12-week randomized open-label study)
2014-000885-23Phase 3Completed
- Sponsor
- GSK
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Clinic visit trough FEV1 on Day 85. Started May 2014; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-000885-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000885-23.